Enrique Garcia-Rivera
VP of AI, Bullfrog AI
Enrique is a technical professional at the intersection of computer science and biology, leveraging data science to solve problems in drug discovery and healthcare. He has led various high-throughput screening efforts at the Broad Institute, most notably for oncology and modulators of protein degradation. At nference, Enrique worked on combining orthogonal data types (-omics, literature, claims, EHR) for use in analytical challenges across the drug development cycle, from early-stage discovery and target identification to post-launch life cycle management. Most recently, he was at ROME Therapeutics, where he developed a cloud-based platform for the quantification of genomic repeats in clinical sequencing data, with a focus on oncology and autoimmune disease. Enrique holds a Ph.D. from Harvard University in Biological and Biomedical Sciences.
Talk to Enrique about these topics and more:
- Machine learning and artificial intelligence for drug discovery
- Natural language processing (NLP) in healthcare
- Precision medicine with genomics and clinical data
Ready to Connect?
Would you like to invite a life science expert to participate in your next piece, program, panel, or partnership? Our team is standing by to help connect you to the right source and topic:
About Bullfrog AI
BullFrog AI is a technology-enabled drug development company that creates and analyzes networks of biological, clinical, and real-world data spanning from early discovery to late-stage clinical trials. Through its partnerships with leading research institutions, BullFrog AI is at the forefront of AI-driven drug development using its proprietary bfLEAP™ artificial intelligence platform. BullFrog AI is deploying bfLEAP™ for use at several critical stages of development with the intention of streamlining data analytics in therapeutics development, decreasing the overall development costs by decreasing failure rates for new therapeutics. Visit BullfrogAI.com
Save this page as a PDF
